TP53 and ovarian cancer: Outstanding synergy was also found in the mutant p53-carrying (Y126C and R337C) cisplatin-resistant ovarian cancer cell line IGROV-1/CDDP (Supplementary Figure S1a and b), which has been established by exposure of the parental wt p53-carrying IGROV-1 cells to cisplatin.17 The IGROV-1 cell line was established from an untreated ovarian cancer patient.18 Moreover, we observed strong synergistic effects with APR-246 and cisplatin in OVCAR-3 cells (Figure 2c).